- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-1 IPO registration
- 1.1 Form of Underwriting Agreement
- 3.1 Certificate of Incorporation of Epien Medical, Inc. (Minnesota)
- 3.2 Articles of Incorporation for Epien Medical, Inc. (Nevada) to Be In Effect Prior to Offering
- 3.3 Amended and Restated Bylaws of Epien Medical, Inc. (Minnesota)
- 3.4 Second Amended and Restated Bylaws (Nevada) to Be In Effect Prior to Closing
- 3.5 Form of Articles of Conversion
- 3.6 Form of Plan of Conversion
- 4.2 Form of Representative's Warrant
- 4.3 Form of Common Stock Purchase Warrant In This Offering
- 4.4 Form of Warrant Agent Agreement Between Epien Medical, Inc. and Vstock Transfer, LLC
- 4.5 Form of Standard Investor Warrant
- 4.6 Form of Investor Warrant for 2005 Bridge Financing
- 4.7 Form of Convertible Promissory Note for 2005 Bridge Financing
- 4.8 Form of Investor Warrant for 2021 Bridge Financing
- 4.9 Form of Poppleton Warrant for 2021 Bridge Financing
- 4.10 Form of Convertible Promissory Note for 2021 Bridge Financing
- 10.1 Stock Option Plan (1998)
- 10.2 Form of Subscription Documents for 2005 Bridge Financing
- 10.3 Form of Subscription Documents for 2021 Bridge Financing
- 10.4 Old National Bank Commercial Credit
- 10.5 Lease Agreement for 4225 White Bear Parkway
- 10.6 Lease Agreement for 600 Highway 169 South
- 10.7 Employment Agreement with Reginald R. Dupre
- 10.8 Employment Agreement with Michael Basara
- 10.9 Employment Agreement with Steven Kavros
- 10.10 Employment Agreement with David Ufheil
- 10.12 Epien Medical, Inc. Equity Incentive Plan (2022)
- 10.13 Epien Medical, Inc. Key Employee/executive Severance and Change of Control Plan
- 10.14 Research Agreement with the University of Miami, Dated January 11, 2022, "Effects of Revity on Dermatophytes Using a Porcine Model"
- 10.15 Amendment No. 1 to Research Agreement with the University of Miami, Dated January 11, 2022, "Effects of Revity on Dermatophytes Using a Porcine Model"
- 10.16 Research Agreement with the University of Miami, Dated August 20, 2021, "Determination of the Debridement Effects of Revity on Deep Dermal Wounds"
- 10.17 Research Agreement with the University of Miami, Dated June 1, 2022, "Evaluation of the Effects of Hybenx Solution on Human Squamous Cell Carcinoma In Mouse Xenograft Model In Vivo"
- 14.1 Form of Code of Ethics of Epien Medical, Inc
- 23.1 Consent of RSM Us LLP
- 99.1 Form of Audit Committee Charter
- 99.2 Form of Compensation Committee Charter
- 99.3 Form of Nominating and Corporate Governance Committee Charter
- 99.4 Consent of Anne B. Moottz, Cpa
- 99.5 Consent of Mark D. P. Davis, MD
- 99.6 Consent of William A. Faubion, MD
- EX-FILING FEES Filing Fee Table
- 21 Mar 23 RW Registration withdrawal request
-
30 Sep 22 S-1 IPO registration
Exhibit 10.16
RESEARCH AGREEMENT
Amendment No. 1
(Non-Clinical)
This Amendment (“Amendment”) entered into this 25th day of January, 2022 (“Amendment Effective Date”), by and between the University of Miami, (“University”) and Epien Medical (“Company”) amends the agreement between the parties dated August 20, 2021 (“Agreement”) which is incorporated by referenced herein and made part of this Amendment.
Whereas, University and Company entered into the Agreement for the a study entitled: Determination of the Debridement Effects of Revity on Deep Dermal Wounds in a Porcine Model (“Study”).
Whereas, University and Company intend to amend the Agreement as follows:
1. The amount of funding for the conduct of the Study is being increased by $15,541.00. The total amount of funding is hereby amended to a total of $38,902.00.
2. Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall apply and remain in full force and effect. All terms used herein shall have the same meaning as ascribed to them in the Agreement. To the extent any term or provision of this Amendment conflicts with any term or provision of the Agreement, the terms and provisions of this Amendment shall prevail.
[Remainder of page left intentionally blank]
IN WITNESS THEREOF, the parties have executed this Amendment by their duly authorized officers or representatives:
UNIVERSITY OF MIAMI: | ||
/s/ D. Stewart MacIntyre III, JD | ||
Authorized University Representative | ||
D. Stewart MacIntyre III, JD | ||
Director, Office of Research Administration | ||
Name and Title | ||
Feb 22, 2022 | ||
Date |
Read and Understood: | ||
PRINCIPAL INVESTIGATOR | ||
/s/ Stephen C. Davis | 2/4/2022 | |
Stephen C. Davis | Date | |
Research Professor | ||
University of Miami Miller School of Medicine | ||
Department of Dermatology & Cutaneous Surgery |